Dr. Sparano on Application of Liquid Biopsies in Breast Cancer

Video

In Partnership With:

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses the application of liquid biopsies in breast cancer.

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses the application of liquid biopsies in breast cancer.

He says that while a liquid biopsy has some advantages over the standard tissue biopsy, there are some challenges that remain before it becomes part of routine clinical practice. The biggest challenge is that liquid biopsies have not yet been clinically proven to result in beneficial treatment for patients. While they are useful in detecting the mutational profile of a tumor, there is still work to be done in improving their clinical utility.

There might be some exceptions to that, says Sparano. Liquid biopsies can be useful in detecting ESR1 mutations, which are frequently found in the blood and usually come as a result of resistance to aromatase inhibition for patients with estrogen receptor-positive disease. Liquid biopsies are also effective in locating circulating tumor DNA.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD